Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib
June 25 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O:
CORVUS PHARMACEUTICALS ANNOUNCES PARTNER ANGEL PHARMACEUTICALS RECEIVED IND APPROVAL FOR A PHASE 1B/2 CLINICAL TRIAL OF SOQUELITINIB IN CHINA FOR THE TREATMENT OF ATOPIC DERMATITIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

From Underdog to AI Infrastructure Leader: Is AMD Poised for Growth in 2026?

Tradingkey







